Insider Transactions in Q4 2025 at Artiva Biotherapeutics, Inc. (RTVA)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2025
|
Fred Aslan President and CEO |
SELL
Open market or private sale
|
Direct |
3,187
-0.26%
|
$19,122
$6.0 P/Share
|
|
Dec 12
2025
|
Christopher Horan Chief Tech Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
107,156
+36.64%
|
-
|
|
Dec 12
2025
|
Heather Raymon SVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
67,253
+38.63%
|
-
|
|
Dec 12
2025
|
Fred Aslan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
869,136
+41.74%
|
-
|
|
Dec 12
2025
|
Jennifer Bush COO, CLO, Secy, Compliance Off |
BUY
Grant, award, or other acquisition
|
Direct |
84,877
+26.71%
|
-
|
|
Nov 17
2025
|
Fred Aslan President and CEO |
SELL
Open market or private sale
|
Direct |
6,375
-1.82%
|
$19,125
$3.38 P/Share
|
|
Nov 15
2025
|
Fred Aslan President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,347
-1.78%
|
$19,041
$3.25 P/Share
|
|
Nov 15
2025
|
Neha Krishnamohan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,490
-3.39%
|
$10,470
$3.25 P/Share
|
|
Nov 15
2025
|
Jennifer Bush COO, CLO, Secy, Compliance Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,055
-2.02%
|
$9,165
$3.25 P/Share
|
|
Nov 15
2025
|
Christopher Horan Chief Tech Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,899
-2.37%
|
$5,697
$3.25 P/Share
|
|
Nov 15
2025
|
Heather Raymon SVP, Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-3.36%
|
$4,125
$3.25 P/Share
|
|
Oct 17
2025
|
Fred Aslan President and CEO |
SELL
Open market or private sale
|
Direct |
25,500
-6.67%
|
$153,000
$6.0 P/Share
|